Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kenneth Anderson
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Acetylon Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Kenneth Anderson is the co-PI of this grant, and will help Dr. Hideshima plan, carry out, analyze, and publish proposed studies to define the role of HDAC3 in myeloma biology (Aim 1), as well as validate prototype inhibitors using the in vitro (Aim 2) and in vivo (Aim 3) models of myeloma in the bone marrow microenvironment. Dr. Anderson’s financial interest in Acetylon is related to this grant because the company is developing small molecule inhibitors that target chromatin modifying enzymes, including HDAC and could have an interest in the results of this grant. Accordingly, the Dana-Farber Cancer Institute Conflicts of Interest Committee determined that a reasonable person could conclude that Dr. Anderson’s interests Acetylon Pharmaceuticals could affect the design, conduct, or reporting of this research, and that this Management Plan is required to ensure the integrity of the research.
Functional and biologic significance of deacetylase3 inhibition in myeloma
Multiple myeloma (MM) is an incurable plasma cell malignancy, and novel therapeutic agents are urgently needed. Non-selective deacetylase (DAC) inhibitors show remarkable anti-myeloma (MM) activity; however, their clinical utility is limited by adverse effects. This project investigates biologic and functional significance of DAC3 in MM, as well as produces and preclinically validates novel selective DAC3 inhibitors for translation to clinical trials to improve patient outcome in MM.
Filed on January 28, 2015.
Tell us what you know about Kenneth Anderson's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Kenneth Anderson filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Kenneth Anderson | Dana Farber Cancer Inst | Conflict of Interest | Acetylon Pharmaceuticals | $60,000 - $79,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.